Gilenya Articles
ANN meeting highlights: Novartis' Gilenya, Lundbeck's Azilect, Orion's ODM-101, Biotie's tozadenant
21 March 2013
Multiple sclerosis drug fingolimod may one day treat colorectal cancer, say US researchers
10 January 2013
Novartis' Gilenya MS patient share growth in Europe likely driven by improved product satisfaction and efficacy-related
9 December 2012
US multiple sclerosis market growth remains centered on Tysabri and Gilenya ahead of Aubagio's launch
28 September 2012
Scotland denies access to Roche skin cancer drug Zelboraf, but OKs Novartis' Gilenya
11 September 2012
US neurologists' adoption of STRATIFY JCV has shifted Tysabri earlier in the treatment of some MS patients
15 August 2012
EMA confirms positive benefit-risk profile for Novartis' Gilenya, but with label change; updated US label
23 April 2012
Germany’s IQWiG finds “hint” of advantage for Novartis’ Gilenya
30 January 2012
UK NICE says Novartis MS drug Gilenya not cost effective, but backs extended use of Roche’s MabThera
1 December 2011
Recent Gilenya growth appears to be coming from initial trial among late adopters not expanded use among existing prescribers
30 November 2011
As global MS pipelines revealed, Gilenya maintains strongest appeal, says Nomura analyst
24 October 2011
Novartis and Vectura’s NVA237 filed in Europe; positive Ph III data at ERS; Gilenya, Ilaris approved in Japan
28 September 2011
Erbitux and Gilenya added to Australia’s PBS listing
2 September 2011
Remicade, Humira and Enbrel made up 40% of the immunomodulators market in 2010; report
23 August 2011
Laquinimod’s modest efficacy means it is no threat to Novartis’ Gilenya in MS, says Nomura
2 August 2011
Strong launch for Novartis’ Gilenya despite its time-consuming initiation process; study
2 June 2011
78% of US health plans will reimburse for emerging oral therapies for multiple sclerosis, study suggests
18 April 2011
Novartis drops Ph III Tasigna trial for GIST; in-licenses Sativex; and reports new Gilenya data
11 April 2011
EU clears Novartis oral multiple sclerosis drug Gilenya
21 March 2011
EMA advisory committee backs Gilenya, Halaven, Jevtana, Pravafenix and Trobalt, but negatives for Fampyra and Multaq
24 January 2011
European neurologists expect significant increases in the use of both Tysabri and Extavia in their multiple sclerosis patients
24 December 2010
Attitudes of US relapsing-remitting multiple sclerosis patients to current and emerging therapies
6 December 2010
Nomura ups sales forecast for Novartis’s new oral MS drug Gilenya to $3.5 billion, as Biogen Idec says it is still confident about non oral products
24 September 2010
Novartis gains FDA approval for Gilenya, first oral MS drug cleared in USA; says SOM230 effective against Cushing’s disease
22 September 2010
Novartis gets Russian approval for oral MS drug Gilenya (fimgolimid)
13 September 2010
Showing 1-33 of 33 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
